# US 2021/0343371 A1 · High-throughput infectious disease diagnosis platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0343371 A1
- Document ID: US20210343371A1
- Status: Published application
- Kind: A1
- Application number: 17/245,006
- Filed: 2021-04-30
- Published: 2021-11-04
- Earliest claimed: 2020-05-01
- Assignees: Intellect Galore, Inc.
- Applicants: Intellect Galore, Inc.
- Inventors: Eung Joon Jo; Chung-Kon Ko
- Web page: https://patentgrep.com/patent/US20210343371A1

## CPC

- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/10: Signal processing, e.g. from mass spectrometry [MS] or from PCR
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B 50/00: ICT programming tools or database systems specially adapted for bioinformatics
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

A sample (e.g. saliva and/or blood) may be takes from a test subject (e.g. a human patient). The sample may be processes to extract a testable substance. The testable substance may be processed by a mass spectrometer in order to generate a mass spectrometry profile of the sample. If the sample includes an infectious disease, then the infectious disease may be reflected in the mass spectrometry profile. The mass spectrometry profile may be compared to a database of mass spectrometry profiles from samples of test subjects whom have already be diagnoses with a particular infectious disease. If the mass spectrometry profile of the test subject being diagnosed is substantially similar to one or more mass spectrometry profiles in the predetermined database, then a diagnosis of an infection disease may be made in an accurate, efficient, and time sensitive manner.

## Claims

### Claim 1

A method comprising:
extracting at least one substance from a sample of a test subject;
generating a mass spectrometry profile from the at least one substance;
comparing the generated mass spectrometry profile to a database comprising a plurality of predetermined mass spectrometry profiles associated with known infectious diseases; and
diagnosing the test subject with at least one of the known infectious diseases if the generated mass spectrometry profile is substantially similar to at least one of the predetermined mass spectrometry profiles associated with the at least one of the known infectious diseases.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least one substance comprises a segment of an RNA gene sequence and/or a segment of a DNA gene sequence.

### Claim 3 (depends on 1)

The method of claim 1, wherein the substance is at least one of:
a protein;
a glycoprotein;
a nucleocapsid protein;
an envelop protein; and/or
a spike protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the substance comprises at least one of:
a glycan;
a N-linked glycan; and/or
an O-linked glycan.

### Claim 5 (depends on 1)

The method of claim 1, wherein the extracting the at least one substance from the sample of the test subject comprises:
swabbing the sample from the test subject nose, throat, and/or saliva using a swab; and
extracting the at least one substance from the swab.

### Claim 6 (depends on 1)

The method of claim 1, wherein the extracting the at least one substance from the sample of the test subject comprises:
drawing the sample in the form of blood from the test subject; and
extracting the at least one substance from the blood.

### Claim 7 (depends on 6)

The method of claim 6, wherein the extracting the at least one substance from the blood comprises:
extracting serum from the blood; and
extracting the at least one substance from the serum.

### Claim 8 (depends on 7)

The method of claim 7, wherein the extracting the at least one substance from the blood comprises an automated process.

### Claim 9 (depends on 1)

The method of claim 1, wherein the generating the mass spectrometry profile comprises using a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometer (MALDI-TOF MS).

### Claim 10 (depends on 1)

The method of claim 1, wherein:
the database is stored in a cloud computing environment; and
the comparing the generated mass spectrometry profile to the database comprising transmitting the generated mass spectrometry profile to the cloud computing environment.

### Claim 11 (depends on 10)

The method of claim 10, wherein the database stored in the cloud computing environment is configured to process geographic attributes of the known infectious diseases.

### Claim 12 (depends on 11)

The method of claim 11, wherein:
the generating the mass spectrometry profile is performed in one of a plurality of mass spectrometers;
the plurality of mass spectrometers are networked to the cloud computing environment; and
at least one component of the cloud computing environment is configured to monitor the known infectious diseases for epidemiological surveillance.

### Claim 13 (depends on 12)

The method of claim 12, wherein at least one component of the cloud computing environment is configured to send information to authorities of the geographic attributes of the known infection diseases.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cloud computing environment is configured to update a local database proximate to at least one of the plurality of mass spectrometers.

### Claim 15 (depends on 1)

The method of claim 1, wherein the diagnosing the test subject with the at least one of the known infectious diseases comprises analyzing the generated mass spectrometry profile to determine a status of the at least one of the known infectious diseases.

### Claim 16 (depends on 15)

The method of claim 15, wherein the status of the at least one of the known infectious diseases comprises at least one of:
identification of at least one pathogen virus;
identification of an antigen; and/or
identification of the immunity status of the test subject to the at least one pathogen virus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the identification of the at least one pathogen virus comprises identification of at least one viral substance.

### Claim 18 (depends on 16)

The method of claim 16, wherein the identification of the immunity status of the test subject comprises identification of at least one antibody of the at least one pathogen virus.

### Claim 19 (depends on 1)

The method of claim 1, wherein at least one of the comparing and/or the diagnosing comprises at least one of:
artificial intelligence;
machine learning; and/or
pattern matching.

### Claim 20

A system comprising:
an extraction unit configured to extract at least one substance from a sample of a test subject;
a mass spectrometer unit configured to generating a mass spectrometry profile from the at least one substance;
a comparison unit configured to compare the generated mass spectrometry profile to a database comprising a plurality of predetermined mass spectrometry profiles associated with known infectious diseases; and
a diagnostic unit configured to diagnose the test subject with at least one of the known infectious diseases if the generated mass spectrometry profile is substantially similar to at least one of the predetermined mass spectrometry profiles associated with the at least one of the known infectious diseases.
